The small-molecule GLP-1 receptor agonist safiglipron improved glucose control and reduced weight in the Phase 3 OUTSTAND-1 trial, without specific fasting or meal-timing restrictions.
Adults with obesity or overweight and type 2 diabetes receiving the investigational 12 mg retatrutide dose lost an average 20.8% of body weight over 80 weeks in TRIUMPH-2.
The first randomized trial to test radiotherapy after complete removal of a WHO grade 2 atypical meningioma found substantially fewer tumour recurrences with immediate radiotherapy than with observation alone. The result addresses a treatment question that has remained uncertain for years, although radiotherapy still carries potential short- and long-term harms that must be weighed for each patient.
A randomized NHS trial involving more than 142,000 people found that adding the Galleri multi-cancer blood test to usual care did not significantly reduce the trial's primary measure of stage III and IV cancers. Some secondary findings were more encouraging, including fewer stage IV cancers, but the evidence does not yet show that the test reduces cancer deaths or should replace established screening programmes.
The investigational treatment ulefnersen has met the primary endpoint of the Phase 3 FUSION trial in people with ALS caused by FUS gene mutations. The RNA-targeted therapy is designed to reduce production of FUS protein, but detailed Phase 3 results have not yet been peer-reviewed and the treatment is not yet approved.
A randomized Phase 2 trial found much deeper responses with teclistamab than with lenalidomide–dexamethasone in people with high-risk smoldering multiple myeloma. The findings raise the possibility of treating dangerous precursor disease earlier, but the trial was small and does not yet show that overt myeloma or death can be prevented.
A randomized trial involving nearly 1,000 people with ischemic stroke found better recovery after treatment with the experimental drug loberamisal, including when treatment began many hours after the stroke. The finding is promising, but further trials are needed before the drug can become established treatment.
A randomized study found major pain relief and improved sensation in people with severe painful diabetic neuropathy treated with high-frequency spinal-cord stimulation, while preliminary tissue findings raised questions about whether nerve changes may extend beyond pain control.
A randomized trial involving nearly 1,700 people found no statistically significant reduction in COPD exacerbations, cardiovascular events or death when metoprolol was added in patients who had no cardiovascular indication for the drug.
An experimental immune-targeting treatment reduced intestinal damage during six weeks of gluten exposure in a small randomized study of adults with celiac disease.
